entertainment -WSS

entertainment

author：explore 2025-09-30 02:09:29 - browse：3834

Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation. — Suzanne Kreiter/Globe staff

WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Artificial intelligence use in health care faces greater scrutiny in 2024

focus

WSS

How generative AI ratchets up security threats for health systems

Too many hospitalized Covid

Report cites 'urgent' need to recruit more diverse clinical trial participants

10 reasons why health care startups fail

Abbott's new heart device gets FDA advisory panel nod

Doctors on social media are being harassed and cyberbullied

focus

entertainment

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Latigo launches with $135 million for Vertex

Medicare details structure of new drug price negotiation program

Medicare Advantage insurers face 0.2% cut to 2025 payments

In Memoriam: Notable people who died in 2023

Tome Biosciences co

Drug repurposing or repositioning? The language matters

10 reasons why health care startups fail

Hepatitis C has a cure — but many Americans still lack access to it

Artificial intelligence use in health care faces greater scrutiny in 2024

hotspot

Reconstructing family trees of blood cells may help predict disease

Ebola vaccine can save some who are already sick, per new study

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Syphilis numbers in the United States reach record heights

FTC sues over Novant Health acquisition of two N.C. hospitals

Eli Lilly reports tirzepatide MASH success during Q4 earnings

focus

focus

focus

Wikipedia